Dahan Michel 4
4 · Akebia Therapeutics, Inc. · Filed May 14, 2024
Insider Transaction Report
Form 4
Dahan Michel
SVP, Chief Business Officer
Transactions
- Sale
Common Stock
2024-05-13$1.26/sh−34,840$43,898→ 672,092 total
Footnotes (2)
- [F1]This sale was made automatically by the Issuer to cover tax withholding obligations in connection with the vesting and settlement of one-third of the reporting person's restricted stock units granted on May 12, 2023.
- [F2]This sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on December 3, 2023.